How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

430 results for

Midodrine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Orthostatic hypotension due to autonomic dysfunction: midodrine

Orthostatic hypotension due to autonomic dysfunction: midodrine Orthostatic h Orthostatic hypotension due to autonomic ypotension due to autonomic dysfunction: midodrine dysfunction: midodrine Evidence summary Published: 6 October 2015 nice.org.uk/guidance/esnm61 pathways This advice replaces ESUOM5. K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in October 2015. See summaries of product characteristics (SPCs), British national (...) formulary (BNF) or the MHRA or NICE websites for up-to-date information. Summary Two randomised controlled trials (RCTs) (n=171 and n=97) found that midodrine significantly increased standing blood pressure 1 hour post-dose compared with placebo in people with symptomatic orthostatic hypotension due to autonomic dysfunction. There was also limited evidence that midodrine improved some symptoms of orthostatic hypotension, such as syncope (fainting) and low energy levels. However, results for other

2015 National Institute for Health and Clinical Excellence - Advice

2. Blood Pressure and Early Mobilization After Total Hip and Knee Replacements: A Pilot Study on the Impact of Midodrine Hydrochloride. Full Text available with Trip Pro

Blood Pressure and Early Mobilization After Total Hip and Knee Replacements: A Pilot Study on the Impact of Midodrine Hydrochloride. Early mobilization is an important therapeutic goal after total knee replacement and total hip replacement. Orthostatic hypotension and orthostatic intolerance can impede mobilization. Midodrine hydrochloride, an orally administered vasoconstrictor, may improve blood pressure and diminish the prevalence of adverse mobilization events.We conducted a pilot change (...) -of-practice study. Two cohorts, each comprising 10 patients managed with total knee replacement and 10 patients managed with total hip replacement, were managed with blood pressure-adjusted midodrine, which was administered 3 times daily for the first 72 hours postoperatively at either a low dose (2.5 or 5 mg) or a higher dose (5 or 10 mg). These patients were then matched with an equivalent preintervention cohort of patients.The midodrine protocol was instituted effectively and with high compliance

2019 JB & JS open access Controlled trial quality: uncertain

3. Midodrine hydrochloride (Bramox) - for the treatment of severe orthostatic hypotension due to autonomic dysfunction

Midodrine hydrochloride (Bramox) - for the treatment of severe orthostatic hypotension due to autonomic dysfunction Final Appraisal Recommendation Advice No: 2915 – October 2015 Midodrine (Bramox ® ) 2.5 mg and 5 mg tablets Submission by Brancaster Pharma Ltd Additional note(s): • The initiation and dose titration of midodrine hydrochloride (Bramox ® ) should be restricted to specialist prescribing. In reaching the above recommendation AWMSG has taken account of the appraisal documentation (...) : No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2915: Midodrine hydrochloride (Bramox ® ) 2.5 mg and 5 mg tablets. October 2015. Recommendation of AWMSG Midodrine hydrochloride (Bramox ® ) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other

2015 All Wales Medicines Strategy Group

4. Midodrine (Bramox) for orthostatic hypotension

Midodrine (Bramox) for orthostatic hypotension Midodrine (Bramox) for orthostatic hypotension Midodrine (Bramox) for orthostatic hypotension NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Midodrine (Bramox) for orthostatic hypotension. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors (...) ' objectives Midodrine (Bramox) is intended to be used as a treatment option for patients with severe orthostatic hypotension. It is licensed in the UK for the treatment of orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other (non-pharmacological) forms of treatment are inadequate. Midodrine is a peripheral α-adrenergic agonist that is almost completely absorbed after oral administration and undergoes enzymatic hydrolysis to form its pharmacologically

2015 Health Technology Assessment (HTA) Database.

5. Midodrine hydrochloride (Bramox®)

Midodrine hydrochloride (Bramox®) Midodrine hydrochloride (Bramox®) Midodrine hydrochloride (Bramox®) All Wales Medicines Strategy Group (AWMSG) Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation All Wales Medicines Strategy Group (AWMSG). Midodrine hydrochloride (Bramox®) Penarth: All Wales Therapeutics and Toxicology Centre (AWTTC), secretariat of the All Wales (...) Medicines Strategy Group (AWMSG). AWMSG Secretariat Assessment Report Advice No. 2650. 2015 Authors' conclusions Midodrine hydrochloride (Bramox®) is recommended for use within NHS Wales for the treatment of severe orthostatic hypotension due to autonomic dysfunction when corrective factors have been ruled out and other forms of treatment are inadequate. Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Autonomic Nervous System Diseases; Heart Rate; Humans; Hypotension

2015 Health Technology Assessment (HTA) Database.

6. Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol. (Abstract)

Effectiveness of droxidopa compared to midodrine in standing blood pressure and orthostatic tolerance in adults with neurogenic orthostatic hypotension: a systematic review protocol. The question of this review is: what is the effectiveness of droxidopa compared to midodrine on standing blood pressure and orthostatic intolerance symptoms in adults with neurogenic orthostatic hypotension?

2017 JBI database of systematic reviews and implementation reports

7. Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. (Abstract)

Continuation of Newly Initiated Midodrine Therapy After Intensive Care and Hospital Discharge: A Single-Center Retrospective Study. Midodrine is an α1-agonist approved for orthostatic hypotension. Recently, it has received attention as an oral vasopressor to facilitate ICU discharge. The purpose of this study was to identify the incidence of continuation of newly initiated midodrine upon ICU and hospital discharge and identify risk factors associated with its occurrence.Single-center (...) retrospective study.ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester.Adult patients admitted to any ICU who received new midodrine for hypotension and survived to discharge.None.During the study period, 1,010 patients were newly started on midodrine and survived to ICU discharge. Midodrine was continued in 67% (672/1,010) of patients at ICU discharge. Admission to cardiovascular surgery ICU and mixed medical/surgical ICU was a risk factor for midodrine continuation at ICU discharge

2019 Critical Care Medicine

8. Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. (Abstract)

Oral midodrine is comparable to albumin infusion in cirrhotic patients with refractory ascites undergoing large-volume paracentesis: results of a pilot study. Albumin infusion reduces the incidence of postparacentesis circulatory dysfunction among patients with cirrhosis and tense ascites compared with no treatment. Less costly treatment alternatives such as vasoconstrictors have been investigated, but the results are controversial. Midodrine, an oral α1-adrenergic agonist, increases effective (...) circulating blood volume and renal perfusion by increasing systemic and splanchnic blood pressure. Our aim is to assess whether or not morbidity in terms of renal dysfunction, hyponatremia, systemic, or portal hemodynamics derangement or mortality differed in patients receiving albumin versus midodrine.Seventy-five patients with cirrhosis and refractory ascites were randomized to receive albumin infusion, oral midodrine for 2 days, or oral midodrine for 30 days after therapeutic large volume paracentesis

2019 European journal of gastroenterology & hepatology Controlled trial quality: uncertain

9. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension (Abstract)

Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension To evaluate the long-term (for up to 3 months) efficacy and safety of single or combined therapy with midodrine and pyridostigmine for neurogenic orthostatic hypotension (OH).This was a randomized, open-label clinical trial. In total, 87 patients with symptomatic neurogenic OH were enrolled and randomized to receive 1 of 3 treatments: midodrine only, pyridostigmine only, or midodrine + pyridostigmine (...) treatment, and the symptom severity was as follows: midodrine only < midodrine + pyridostigmine < pyridostigmine only group. Mild to moderate adverse events were reported by 11.5% of the patients.Single or combination treatment with midodrine and pyridostigmine was effective and safe in patients with OH for up to 3 months. Midodrine was better than pyridostigmine at improving OH-related symptoms.NCT02308124.This study provides Class IV evidence that for patients with neurogenic OH, long-term treatment

2017 EvidenceUpdates

10. The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometry. (Abstract)

The effect of single oral doses of duloxetine, reboxetine, and midodrine on the urethral pressure in healthy female subjects, using urethral pressure reflectometry. To evaluate the effect on urethral pressure of reference drugs known to reduce stress urinary incontinence symptoms by different effect size and mechanisms of action on urethral musculature under four test conditions in healthy female subjects using urethral pressure reflectometry.Healthy females aged 18-55 years were recruited (...) by advertising for this phase 1, single site, placebo-controlled, randomized, four-period, crossover study. The interventions were single oral doses of 10 mg Midodrine, 80 mg Duloxetine, 12 mg Reboxetine, and placebo. The endpoints were the opening urethral pressure measured in each period at four time points (predose and 2, 5.5, and 9 h after dosing).Twenty-nine females were enrolled; 25 randomized and 24 completed the study. The opening urethral pressure was higher in all measurements with filled bladder

2018 Neurourology and urodynamics Controlled trial quality: uncertain

11. Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1.

Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03455322 Recruitment Status

2018 Clinical Trials

12. Midodrine Use in Septic Shock

Midodrine Use in Septic Shock Midodrine Use in Septic Shock - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Midodrine Use in Septic Shock The safety and scientific validity of this study (...) Study Details Study Description Go to Brief Summary: The investigators aim to perform a randomized, double-blind, placebo-controlled trial to investigate the efficacy of midodrine in decreasing time to IV vasopressor liberation in patients with septic shock. Condition or disease Intervention/treatment Phase Septic Shock Drug: Midodrine Hydrochloride Other: placebo Phase 3 Detailed Description: A growing body of literature comprising largely retrospective data seems to support the safety and efficacy

2018 Clinical Trials

13. MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation. (Abstract)

MIDODRINE &ALBUMIN for Preventing COMPLICATIONS IN PATIENTS WITH CIRRHOSIS AWAITING Liver transplantation. Patients with decompensated cirrhosis on the waiting list for liver transplantation (LT) commonly develop complications that may preclude them from reaching LT. Circulatory dysfunction leading to effective arterial hypovolemia and activation of vasoconstrictor systems is a key factor in the pathophysiology of complications of cirrhosis. The aim of this study was to investigate whether (...) treatment with midodrine, an alpha-adrenergic vasoconstrictor, together with intravenous albumin improves circulatory dysfunction and prevents complications of cirrhosis in patients awaiting LT.A multicenter, randomized, double-blind, placebo-controlled trial (NCT00839358) was conducted, including 196 consecutive patients with cirrhosis and ascites awaiting LT. Patients were randomly assigned to receive midodrine (15-30 mg/day) and albumin (40 g/15 days) or matching placebos for one year, until LT

2018 Journal of Hepatology Controlled trial quality: predicted high

14. To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax

To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please (...) remove one or more studies before adding more. To Study the Safety and Efficacy of Midodrine With Albumin Versus Albumin Alone in Hepatic Hydrothorax The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03645642 Recruitment

2018 Clinical Trials

15. The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. (Abstract)

The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Intradialytic hypotension (IDH) is a frequent complication of hemodialysis, and is associated with significant morbidity and mortality. Off-label use of the alpha-1 andrenergic receptor agonist midodrine to reduce the frequency and severity of IDH is common. However, limited data exist to support this practice. This study sought to examine real-world efficacy of midodrine with respect to relevant clinical (...) and hemodynamic outcomes.Here, we compared a variety of clinical and hemodynamic outcomes among adult patients who were prescribed midodrine (n = 1,046) and matched controls (n = 2,037), all of whom were receiving in-center hemodialysis treatment at dialysis facilities in the United States (July 2015 - September 2016). Mortality, all-cause hospitalization, cardiovascular hospitalization, and hemodynamic outcomes were considered from the month following the initiation of midodrine (or corresponding month

2018 American journal of nephrology

16. Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. (Abstract)

Trends in Use of Midodrine in the ICU: A Single-Center Retrospective Case Series. Midodrine is an oral alpha-agonist approved for orthostatic hypotension. The use of midodrine as a vasopressor sparing agent has steadily increased in the ICU despite limited evidence for its safety in that setting. We describe the trends in use and reported side effects and complications of midodrine in multidisciplinary ICUs of a tertiary care institution.Single-center retrospective case series.Medical (...) and surgical ICU patients from January 2011 to October 2016 at Mayo Clinic, Rochester.Adult patients admitted to any ICU who received midodrine for hypotension were eligible.None.We reviewed the mean arterial pressures and cumulative vasopressor dose before and after midodrine administration and assessed for reported complications. During the study period, a total of 1,119 patients were initiated on midodrine, 56% in surgical ICUs, 42% in medical ICUs, and 2% in a mixed medical and surgical neurology ICU

2018 Critical Care Medicine

17. Midodrine in Hepatopumonary Syndrome

Midodrine in Hepatopumonary Syndrome Midodrine in Hepatopumonary Syndrome - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Midodrine in Hepatopumonary Syndrome The safety and scientific validity (...) Details Study Description Go to Brief Summary: This proof-of-concept clinical trial will determine the safety and tolerability of midodrine in patients with hepatopulmonary syndrome (HPS). Exploratory endpoints will assess the effect of midodrine on oxygenation, intrapulmonary shunting and symptoms. Condition or disease Intervention/treatment Phase Hepatopulmonary Syndrome (HPS) Drug: Midodrine Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial

2018 Clinical Trials

18. Use of Selective Serotonin Reuptake Inhibitor and Midodrine in a Patient With Autonomic Instability 2/2 Compressive Squamous Cell Carcinoma and Pain Full Text available with Trip Pro

Use of Selective Serotonin Reuptake Inhibitor and Midodrine in a Patient With Autonomic Instability 2/2 Compressive Squamous Cell Carcinoma and Pain A rare cause of reflex syncope is metastatic cancers involving the head and neck. These can irritate the glossopharyngeal nerve and lead to glossopharyngeal neuralgia with associated syncope. This type of syncope is difficult to treat since it commonly involves both a vasodepressor and cardioinhibitory response, and typically requires removal (...) was started on sertraline and midodrine with resolution of syncope. This could be a potential treatment option in those with compressive mixed syncope who are not candidates for surgery or chemotherapy or are awaiting definitive treatment.

2018 Journal of investigative medicine high impact case reports

19. Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury

Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum (...) number of saved studies (100). Please remove one or more studies before adding more. Midodrine is Effective in Management of Intradialytic Hypotension Among Critically-ill Patients With Acute Kidney Injury The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03431194 Recruitment Status : Completed First

2018 Clinical Trials

20. Use of midodrine with vasopressors in the intensive care unit

Use of midodrine with vasopressors in the intensive care unit Use of midodrine with vasopressors in the intensive care unit Use of midodrine with vasopressors in the intensive care unit Lavenberg JG, Umscheid CA Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lavenberg JG, Umscheid CA. Use of midodrine with vasopressors in the intensive care unit. Philadelphia (...) : Center for Evidence-based Practice (CEP). 2013 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Intensive Care Units; Midodrine; Vasoconstrictor Agents Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence Center for Evidence-based Practice, University of Pennsylvania Health System, 3535 Market St. Suite 50, Philadelphia PA 19104 Email: Cep2@uphs.upenn.edu AccessionNumber

2013 Health Technology Assessment (HTA) Database.

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>